AstraZeneca and Daiichi Sankyo look likely to gain a first approval for their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), later this year, but for a much smaller patient group than originally desired.
AstraZeneca And Daiichi’s Dato-DXd Set For More Modest Market Entry Than First Hoped
After setbacks and a withdrawn filing, Dato-DXd is back on track for a potential second-line approval later this year in EGFR-mutant lung cancer. The partners are still counting on success in first line lung cancer and breast cancer treatment
More from Anticancer
More from R&D
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus